See What HealthDay Can Do For You
Contact Us

Reclast Approved as Once-Yearly Osteoporosis Drug

For postmenopausal women

MONDAY, Aug. 20, 2007 (HealthDay News) -- The Novartis drug Reclast (zoledronic acid) has been approved by the U.S. Food and Drug Administration as a once-yearly treatment for postmenopausal osteoporosis, the company said Monday.

In a clinical study involving more than 7,700 women, Reclast reduced the risk of spine fracture by 70 percent and hip fracture by 41 percent, the company said in a statement. The drug is administered as a 15-minute intravenous injection.

The most common side effects reported were pain in the muscles, joints, or bones; flu-like symptoms, and headache.

Osteoporotic fractures lead to about 800,000 emergency room visits, 500,000 hospitalizations, 180,000 nursing home placements, and 2.6 million doctor visits each year, costing up $17.9 billion annually, Novartis said.

In April, Reclast was approved to treat another bone disorder, Paget's disease, which affects about 1 million people in the United States.

More information

Visit this FDA page to learn more about osteoporosis.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.